Aspire Private Capital LLC Acquires 319 Shares of Boston Scientific Co. (NYSE:BSX)

Aspire Private Capital LLC increased its holdings in Boston Scientific Co. (NYSE:BSXFree Report) by 2.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,132 shares of the medical equipment provider’s stock after buying an additional 319 shares during the period. Aspire Private Capital LLC’s holdings in Boston Scientific were worth $1,084,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Boston Scientific by 4.4% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider’s stock worth $345,205,000 after acquiring an additional 173,034 shares during the period. Mechanics Bank Trust Department purchased a new position in Boston Scientific during the 4th quarter valued at about $415,000. Brookstone Capital Management increased its position in shares of Boston Scientific by 23.7% during the fourth quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider’s stock valued at $9,455,000 after buying an additional 20,307 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Boston Scientific by 5.9% in the third quarter. Principal Financial Group Inc. now owns 2,010,441 shares of the medical equipment provider’s stock worth $168,475,000 after buying an additional 111,724 shares in the last quarter. Finally, HWG Holdings LP bought a new position in shares of Boston Scientific in the second quarter valued at approximately $482,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 2.3 %

Shares of BSX opened at $100.90 on Wednesday. Boston Scientific Co. has a 1-year low of $59.85 and a 1-year high of $101.14. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $91.21 and its 200-day moving average price is $84.76. The firm has a market capitalization of $148.71 billion, a price-to-earnings ratio of 83.39, a PEG ratio of 2.59 and a beta of 0.80.

Boston Scientific (NYSE:BSXGet Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.04 billion. During the same period in the previous year, the firm posted $0.50 EPS. The business’s revenue was up 19.3% on a year-over-year basis. Sell-side analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of analyst reports. BTIG Research upped their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Stifel Nicolaus increased their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Citigroup boosted their target price on Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada boosted their price objective on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group lifted their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $97.26.

View Our Latest Analysis on BSX

Insider Activity at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares of the company’s stock, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares in the company, valued at $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,989 shares of company stock worth $2,702,261 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Recommended Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.